Preclinical in vivo efficacy of two 9-dihydrotaxane analogues against human and murine tumours
1996

Efficacy of Two Taxane Analogues Against Tumors

Sample size: 20 publication Evidence: moderate

Author Information

Author(s): JD Alder, KP Jarvis, KC Marsh, LL Klein, JJ Clement

Primary Institution: Abbott Laboratories

Hypothesis

Do the 9-dihydrotaxane analogues show improved efficacy and reduced toxicity compared to paclitaxel in treating tumors?

Conclusion

The 9-dihydrotaxane analogues demonstrated greater efficacy and lower toxicity compared to paclitaxel in preclinical models.

Supporting Evidence

  • The analogues yielded cure rates greater than 60% against human MX-1 solid tumor xenografts.
  • Both analogues were at least 20-fold more soluble than paclitaxel in water.
  • 9-DH-t produced serum concentrations greater than paclitaxel, while 10-DeAc-9-DH-t yielded lower concentrations.

Takeaway

Scientists tested two new cancer drugs in mice and found they worked better and were less harmful than an existing drug called paclitaxel.

Methodology

The study involved synthesizing two taxane analogues and testing their efficacy against various tumor models in mice, including both solid and ascites tumors.

Limitations

The study was conducted in mice, which may not fully predict human responses.

Participant Demographics

Female C57BL/6 x DBA/2F1 mice and Hsd:Athymic Nude mice were used in the experiments.

Statistical Information

P-Value

p<0.05

Statistical Significance

p<0.05

Want to read the original?

Access the complete publication on the publisher's website

View Original Publication